Brief: Nicox H1 Operating Loss Widens To 7.6 Million Euros

Nicox SA

10/09/2020 06:41

Sept 10 (Reuters) - Nicox SA  NCOX.PA :
    * H1 NET LOSS -14.6 MILLION EUR VERSUS -800,000 EUR LOSS
YEAR AGO
    * H1 2020 NET REVENUE OF EUR 2.4 MILLION AND CASH POSITION
OF EUR
45.4 MILLION INCLUDING EUR 5 MILLION FROM DIVESTMENT OF
VISUFARMA SHAREHOLDING RECEIVED IN JULY
    * NCX 470 MONT BLANC PHASE 3 CLINICAL TRIAL INITIATED ON
SCHEDULE
AND ON TRACK FOR ADAPTIVE DOSE SELECTION IN Q4 2020
    * DOSE SELECTION WILL ENABLE START OF SECOND PART OF MONT
BLANC
TRIAL AND INITIATION OF SECOND PHASE 3 TRIAL, DENALIs"
    * POST-FIRST HALF CLOSING EUR 2 MILLION LOAN FACILITY
GUARANTEED
BY FRENCH STATE SECURED, BRINGING NON-DILUTIVE FINANCING TO DATE
IN 2020 TO EUR 22 MILLION
    * AS OF JUNE 30, 2020, NICOX GROUP HAD FINANCIAL DEBT OF EUR
17.7
MILLION
    * H1 OPERATING LOSS EUR 7.6 MILLION VERSUS LOSS OF EUR 5.3
MILLION
YEAR AGO

Source text for Eikon:  ID:nGNEbM0Mpm 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))